鄉下的妹子太便宜，一次四個都要了[12P]

stcar

good good support

dadiaoguang

谢谢

wyp5888

好图，谢谢分享。

wudaode

11

xxp13136

大家好心情

weihai

果您要查看本帖隱藏內容請

q2367975099

看看再说

金正恩

将计就计

zidantiao

真的很不错

kaifka

RESPONSE OF MICROPENIS TO TOPICAL TESTOSTERONE AND
GONADOTROPIN
- ^" M# F' _$ x2 F) [RICHARD C. KLUGO* AND JOSEPH C. CERNY
/ M0 l4 A3 f* N& L  [& |' RFrom the Division of Urology, Henry Ford Hospital, Detroit, Michigan
ABSTRACT
3 X$ |# D* `& R0 Z. j6 o7 J9 @" p. RFive patients were treated with gonadotropin and topical testosterone for micropenis associated
with hypothalamic hypogonadotropic hypogonadism. All patients received 1,000 units of gonado-
+ }* N+ p2 f& _) S, otropin weekly for 3 weeks, with a 6-week interval followed by 10 per cent topical testosterone
cream twice daily for 3 weeks. Serum testosterone levels were measured and remained equivalent
: d% [3 H. V! ~) @" hfor both modes of therapy. Average penile growth response with gonadotropin was 14.3 per cent
increase in length and 5.0 per cent increase of girth. Topical testosterone produced an average
6 g0 d7 S- g/ p! H: W' G, J; lincrease of 60 per cent in penile length and 52. 9 per cent in girth. The greatest growth response
occurred in prepuberal male subjects with a minimal response in postpuberal male subjects. This
) y4 b5 n2 ?1 _8 v& ~# m. }- Kstudy suggests that 10 per cent topical testosterone cream twice daily will produce effective penile
growth. The response appears to be greater in younger children, which is consistent with previ-
ously published studies of age-related 5 reductase activity.
Children with microphallus regardless of its etiology will
require augmentation or consideration for alteration of exter-
6 S9 D1 l4 D9 `2 Unal genitalia. In many instances urethroplasty for hypo-
7 }6 w8 N& |1 {. ^% j7 Bspadias is easier with previous stimulation of phallic growth.
The use of testosterone administered parenterally or topically
+ i) d) a6 g+ dhas produced effective phallic growth. 1- 3 The mechanism of
& o+ Z4 ?6 p9 `8 I' A- u$ Nresponse has been considered as local or systemic. With this
in mind we studied 5 children with microphallus for response
to gonadotropin and to topical testosterone independently.
MATERIALS AND METHODS
' p! R* x8 O( z1 U3 E5 Q2 cFive 46 XY male subjects between 3 and 17 years old were
7 a- P& A$ C2 C4 B, F3 J" |2 v* `0 wevaluated for serum testosterone levels and hypothalamic
function. Of these 5 boys 2 were considered to have Kallmann's
syndrome, 1 Prader-Willi syndrome and 2 idiopathic hypotha-
2 T) ]! z" B8 G# K0 ^$ Clamic deficiency. After evaluation of response to luteinizing
) S$ u8 _3 v! q3 c% uhormone-releasing hormone these patients were treated with
/ t1 R* b$ G7 l9 h1,000 units of gonadotropin weekly for 3 weeks. Six weeks
after completion of gonadotropin therapy 10 per cent topical
, v: Q9 A$ P$ J* htestosterone was applied to the phallus twice daily for 3 weeks.
, h/ ?' E  B+ W+ E0 QSerum testosterone, luteinizing hormone and follicle-stimulat-
ing hormone were monitored before, during and after comple-
tion of each phase of therapy. Penile stretch length was
0 P  @# F" v1 ?. c9 h0 a  v$ gobtained by measuring from the symphysis pubis to the tip of
' `; d3 O+ s/ k( y" R9 athe glans. Penile circumferential (girth) measurements were
obtained using an orthopedic digital measuring device (see
figure).
RESULTS
" Z4 N( o7 M# k/ cSerum testosterone increased moderately to levels between
' V% A0 |5 T+ {8 {+ W% G50 and 86 ng./dl. with gonadotropin stimulation. Serum testos-
) B: b% l- a& v% lterone levels with topical testosterone remained near pre-
, r4 w" Z8 x# E, M9 j5 f  Q; ~treatment levels (35 ng./dl.) or were elevated to similar levels
developed after gonadotropin therapy (96 ng./dl.). Higher
serum levels were noted in older patients (12 and 17 years old),
while lower levels persisted in younger patients (4, 8, and 10
: g. r% v" i1 @' M# q7 M- j4 @: z# J- Tyears old) (see table). Despite absence of profound alterations
$ u+ r' h5 n! n1 t# [  wof serum testosterone the topical therapy provided a greater
Accepted for publication July 1, 1977. ·
' J) {" C6 J1 M/ F% j# @Read at annual meeting of American Urological Association,
Chicago, Illinois, April 24-28, 1977.
* Requests for reprints: Division of Urology, Henry Ford Hospital,
% `/ F) o1 r, z# f2 X  J2799 W. Grand Blvd., Detroit, Michigan 48202.
1 d5 Y8 N+ i; z, {' simprovement in phallic growth compared to gonadotropin.
Average phallic growth with gonadotropin was 14.3 per cent
( [. Y& n  Z3 x6 Qincrease in length and 5.0 per cent increase of girth. Topical
" T* A( G0 ]* D. Ztestosterone produced a 60.0 per cent increase of phallic length
8 i4 W$ T# T5 N/ p( l4 wand 52.9 per cent increase of girth (circumference). The
& v  `2 K7 \- {2 O7 Xresponse to topical testosterone was greatest in children be-
! U' U4 K) [* A! M- _tween 4 and 8 years old, with a gradual decrease to age 17
years (see table).
. }' x7 g4 {. c' e$ s4 B& w- ?DISCUSSION
- v. H1 @. ^, ?$ fTopical testosterone has been used effectively by other
8 @" B+ {; T, X% W5 Y7 t& Iclinicians but its mode of action remains controversial. Im-
mergut and associates reported an excellent growth response
to topical testosterone with low levels of serum testosterone,
4 M+ B* |& S: k! H; y7 Gsuggesting a local effect.1 Others have obtained growth re-
sponse with high. levels of serum testosterone after topical
4 J3 u$ l3 X+ [! x+ ?administration, suggesting a systemic response. 3 The use of
gonadotropin to obtain levels of serum testosterone compara-
ble to levels obtained with topical testosterone would seem to
provide a means to compare the relative effectiveness of
topical testosterone to systemic testosterone effect. It cer-
tainly has been established that gonadotropin as well as par-
' H% f" r1 N+ ^% ^" Renteral testosterone administration will produce genital
* r6 F: d5 |, F/ X# zgrowth. Our report shows that the growth of the phallus was
# _, d* R% T) g$ v5 e' D% b: ^significantly greater with topical applications than with go-
nadotropin, particularly in children less than 10 years old.
9 Z. L0 K% i- n- K4 z2 hThe levels of serum testosterone remained similar or lower
than with gonadotropin during therapy, suggesting that topi-
cal application produces genital growth by its local effect as
well as its systemic effect.
Review of our patients and their growth response related to
age shows a greater growth response at an earlier age. This is
consistent with the findings of Wilson and Walker, who
reported an increased conversion of testosterone to dihydrotes-
- V, m" M5 O% [- Vtosterone in the foreskin of neonates and infants.4 This activ-
ity gradually decreases with age until puberty when it ap-
proaches the same level of activity as peripheral skin. It may
+ O9 s! I3 R- N; ^9 B0 z0 w/ i% uwell be that absorption of testosterone is less when applied at
/ Z8 c7 y4 q0 y9 dan earlier age as suggested by lower serum levels in children
) m0 m) c* x! c, Hless than 10 years old. This fact may be explained by the
greater ability of phallic skin to convert testosterone to dihy-
, `0 r3 V0 A; \9 H- _7 Q, W( h4 L8 Ldrotestosterone at this age. Conversely, serum levels in older
( \( \$ V; J" C# qpatients were higher, possibly because of decreased local
- a  v, B- b/ l/ U: y2 E667
668 KLUGO AND CERNY
Pt. Age
& O' d; q8 k- o) B1 o(yrs.)
Serum Testosterone Phallus (cm.) Change Length
' ~: K. H) w& I; ~2 [! g$ a6 e(ng./dl.) Girth x Length (%)
4
; }# q! y8 r) z- X7 j/ y& y8
3 f% v2 T/ `6 y' U0 o5 [10
' @$ W9 |& D; {4 I% L$ I" [12
! t/ `: x' V6 K: K& w17
$ h! B) L9 i8 _! Z: \Gonadotropin
71.6 2.0 X 3 16.6
# {: K( U6 O: [5 G) k50.4 4.0 X 5.0 20.0
22.0 4.5 X 4.0 25.0
+ l/ O* Q: d: m' G7 D3 j5 f) _) g84.6 4.0 X 4.5 11.1
/ }: z& p" ^$ U+ q$ I. R85.9 4.5 X 5.5 9.0
Av. 14.3
4
8
) c2 I! k& z( i. y10
( e1 t+ [& r& w0 r12
% |' \. j) Z# S9 V17
; W3 A0 E  L9 s7 O- ?, XTopical testosterone
34.6 4.5 X 6.5 85
38.8 6.0 X 8.5 70
0 K. U; v0 P3 T$ D) ~' H0 R3 l40.0 6.0 X 6.5 62.5
93.6 6.0 X 7.0 55.5
: ]& ?# c8 n3 x# |; y6 i95.0 6.5 X 7.0 27.2
4 s/ Z: ~7 b* |- wAv. 60.0
# }: Y, W% Q+ O! `% j  S0 S, Y) tavailable testosterone. Again, emphasis should be placed on
2 n8 C( ?1 `, R( jearly therapy when lower levels of testosterone appear to
provide the best responses. The earlier therapy is instituted
  S8 U& x% e2 `3 M  ?the more likely there will be an excellent response with low
8 H9 z2 W6 J$ p2 A! A% Cserum levels. Response occurs throughout adolescence as
noted in nomograms of phallic growth. 7 The actual response
to a given serum level of testosterone is much greater at birth
5 o# i0 G0 n8 Y, c! k! ^! o$ B5 Hand gradually decreases as boys reach puberty. This is most
likely related to the conversion of testosterone to dihydrotes-
tosterone and correlates well with the studies of testosterone
5 f; Q% U% v; Y1 Hconversion in foreskin at various ages.
The question arises regarding early treatment as to whether
one might sacrifice ultimate potential growth as with acceler-
ated bone growth. The situation appears quite the reverse
with phallic response. If the early growth period is not used
when 5a reductase activity is greatest then potential growth
9 P1 m  d# M5 K$ R, Imay be lost. We have not observed any regression of growth
attained with topical or gonadotropin therapy. It may well
be that some patients will show little or no response to any
9 C$ ]. S8 j: e( u4 ^. qform of therapy. This would suggest a defect in the ability to
$ I+ ]0 f) H6 a, ]$ ^+ gconvert testosterone to dihydrotestosterone and indicate that
phallic and peripheral skin, and subcutaneous tissue should
' b1 r0 K" b. N( sbe compared for 5a reductase activity.
A, loop enlarges to measure penile girth in millimeters. B,
example of penile girth computed easily and accurately.
conversion of testosterone to dihydrotestosterone. It is in this
older group that others have noted high levels of serum
testosterone with topical application. It would also appear
) S+ l' A; W) [that phallic response during puberty is related directly to the
serum testosterone level. There also is other evidence of local
- s& l" w: X- F* M0 r3 i5 Gresponse to testosterone with hair growth and with spermato-
, y! \' W& G4 K1 \. A* Dgenesis. 5• 6
/ _7 n4 o' o5 h4 c; G4 WAdministration of larger doses of gonadotropin or systemic
testosterone, as well as topical applications that produce
higher levels of serum testosterone (150 to 900 ng./dl.), will
also produce phallic growth but risks accelerated skeletal
9 i9 O: p5 W  H) Rmaturation even after stopping treatment. It would appear
that this may be avoided by topical applications of testosterone
and monitoring of serum testosterone. Even with this control
- F3 i  j* M, F: y( m2 h3 xthe duration of our therapy did not exceed 3 weeks at any
$ r* w2 S# T% J. _3 b* L, n6 Ktime. It is apparent that the prepuberal male subject may
' w4 a% H) b7 O' _) Z. s3 f$ x: Fsuffer accelerated bone growth with testosterone levels near
200 ng./dl. When skeletal maturation is complete the level of
2 i# P$ U# H, ^- c( }serum testosterone can be maintained in the 700 to 1,300 ng./
dl. range to stimulate phallic growth and secondary sexual
changes. Therefore, after skeletal maturation parenteral tes-
tosterone may be used to advantage. Before skeletal matura-
# @* I  U4 P+ j* X3 Q) n4 Ztion care must be taken to avoid maintaining levels of serum
: F) I3 M/ ?% h1 vtestosterone more than 100 ng./dl. Low-dose gonadotropin
; A7 S& `9 E3 M) u9 u& W! F! mdepends upon intrinsic testicular activity and may require
- H4 L# ?0 ^# R1 Y% {, y6 @prolonged administration for any response.
' E  F4 }% ?1 q" s: Y. aAlternately, topical testosterone does not depend upon tes-
* j' Q3 b2 D6 C" u' s) ^- aticular function and may provide a more constant level of
REFERENCES
1. Immergut, M., Boldus, R., Yannone, E., Bunge, R. and Flocks,
; V, F+ y3 u7 K( `' K8 V1 bR.: The local application of testosterone cream to the prepub-
% W0 q9 U: H# h: Tertal phallus. J. Urol., 105: 905, 1971.
3 q: V+ [  B8 T: {, j& s$ q/ e: W2. Guthrie, R. D., Smith, D. W. and Graham, C. B.: Testosterone
treatment for micropenis during early childhood. J. Pediat.,
83: 247, 1973.
3 T6 N- h2 F4 z, C3. Jacobs, S. C., Kaplan, G. W. and Gittes, R. F.: Topical testoster-
, Y/ h0 g' H/ M6 h$ |one therapy for penile growth. Urology, 6: 708, 1975.
4. Wilson, J. D. and Walker, J. D.: The conversion of testosterone
. ^+ V% d9 M  }& P6 z* L: F) eto 5 alpha-androstan-17 beta-01-3-one (dihydrotestosterone) by
skin slices of man. J. Clin. Invest., 48: 371, 1969.
9 u5 d7 j) O6 I1 D: R5. Papa, C. M. and Klingman, A. M.: Stimulation of hair growth
by topical application of androgens. J.A.M.A., 191: 521, 1965.
- Z* s) q8 t, b: ~9 m! o6. Gittes, R. F., Smith, G., Conn, C. A. and Smith, F.: Local
androgenic effect of interstitial cell tumor of the testis. J.
& d" O5 q" M7 S; RUrol., 104: 774, 1970.
7. Schonfeld, W. A. and Beebe, G. W.: Normal growth and varia-
" B8 R* L5 l3 G. M6 I4 P2 [! [tion in the male genitalia from birth to maturity. J. Urol., 48: